New York-based Royalty Pharma has, arguably, done the same thing

Bristol-Myers Squibb Co., of New York, and Abbvie Inc., of Chicago, announced updated efficacy and safety data from a small, randomized Phase II, open-label study in patients with previously treated multiple myeloma that evaluated two doses of the investigational monoclonal antibody elotuzumab (10 mg/kg and 20 mg/kg) in combination with lenalidomide and low-dose dexamethasone

and New York-based Pfizer Inc

Intercept Pharmaceuticals Inc., of New York, commenced an underwritten public offering of about 1.7 million shares of its common stock

Bristol-Myers Squibb Co. (BMS), of New York, and Simcere Pharmaceutical Group, of Nanjing, China, expanded their strategic relationship formed in 2010

Researchers from New York University have discovered how fingertips regenerate, and why whole fingers don't

As part of that process Royalty Pharma, of New York, will be invited to participate...Intellicell BioSciences Inc., of New York, said its cellular laboratory facility underwent a thorough inspection by the FDA

New York) LAMA/LABA Aclidinium bromide and formoterol fumarate delivered in the Pressair inhaler Phase III data demonstrated statistically significant Phase III data demonstrated statistically significant improvements with the 400/12 mcg combination in change from baseline for the co-primary endpoints of forced expiratory volume at one hour post-dose 5/2/13 Astellas Pharma Europe BV (Meppel, the Netherlands) Vesomni Solifenacin + tamsulosin Benign prostatic hyperplasia The Dutch Medicines

5/23/13 GASTROINTESTINAL Synergy Pharmaceuticals Inc. (New York) Plecanatide A guanylate cyclase-C agonist Chronic idiopathic constipation Showed it demonstrated statistically significant improvement vs

personalized cancer vaccine Advanced ovarian cancer Interim Phase II data showed a positive tumor immune response as measured by enzyme-linked immunospot analysis in 71% of patients 5/16/13 Gtx Inc. (Memphis, Tenn.) Gtx-024 A selective androgen receptor modulator Metastatic breast cancer Started a Phase II study 5/1/13 Izun Pharmaceuticals Corp. (New York) IZN-6N4 Oral rinse Oral mucositis in head and neck cancer Expanded its ongoing Phase II trial to two additional centers, Memorial Sloan

For Phase III drugs, this could be a year of buyers' market," Neel Patel, director of New York-based Campbell Alliance, said at the conference

Ohr Pharmaceutical Inc., of New York, said it received confirmation that its application to list on Nasdaq was approved...Zealand Pharma A/S, of Copenhagen, signed a collaboration agreement with D.E. Shaw Research LLC., of New York, to combine Shaw's molecular dynamics simulations with Zealand's capabilities in peptide drug development

and Sun Pharmaceutical Industries Ltd. $2.15 billion in a settlement reached with Pfizer Inc., of New York, and Nycomed A/S, now part of Takeda Pharmaceutical Co

The work was presented at the New York Academy of Sciences Conference on Probiotics, Prebiotics and the Host Microbiome: The Science of Translation, and results indicated that RP-G28 significantly altered the microbiomes of 82 percent of the study participants who received the treatment

Bristol-Myers Squibb Co., of New York, reported year two data from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis Subjects With Background Methotrexate) trial of 646 patients comparing the safety and efficacy of the subcutaneous formulation of abatacept (Orencia) vs

Under the terms of the licensing deal, Emory earned royalties from Emtriva sales until mid-2005, when Foster City, Calif.-based Gilead and New York-based Royalty Pharma bought out the university's royalty interest for $525 million in cash, about 60 percent of which went to Emory. (See BioWorld Today, July 20, 2005.) But in the intervening years, funding those early stage programs beyond the tech transfer office has been a growing source of frustration for the drug development industry...New York

New York-based Pfizer is responsible for development and commercializing PDCs, though the pair will work on preclinical research together...San Diego-based Ambrx Inc.'s site-specific ADC platform drew Bristol-Myers Squibb Co., of New York, for a third deal in May

On Monday afternoon, Elan voluntarily withdrew its lawsuit filed a week ago in the U.S. District Court for the Southern District of New York to compel corrective disclosure in Royalty Pharma's tender offer documents

On Monday afternoon, Elan voluntarily withdrew its lawsuit filed a week ago in the U.S. District Court for the Southern District of New York to compel corrective disclosure in Royalty Pharma's tender offer documents